BAM15 vs SANA (MVD1)
BAM15 (C-tier) vs SANA (MVD1) (B-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.
BAM15 — tier C
a preclinical mitochondrial protonophore that reduced fat gain and improved metabolic measures in mice, with no human exposure, dose-finding, or safety study.
BAM15 has a coherent mechanism and credible mouse metabolic data, but no human bridge and no basis for calling a research-chemical exposure safe.
0 human exposure studies · half-life 1.7 hours in mouse plasma after 10 mg/kg oral gavage; no human half-life · weight loss
SANA (MVD1) — tier B
an investigational nitroalkene small molecule that targets creatine-kinase-dependent thermogenesis, with mouse fat-loss data, a small exploratory 15-day human weight signal, and a high-dose renal safety signal in phase 1.
SANA has a defined identity, a novel creatine-thermogenesis mechanism, mouse efficacy, and direct human PK, but the phase 1 renal signal makes dose-dependent safety the central fact.
41 participants across the first-in-human phase 1 program · half-life approximately 1.6 to 2.0 hours in the first-in-human oral phase 1 study · weight loss
at a glance
- BAM15: tier C · 0 human exposure studies
- SANA (MVD1): tier B · 41 participants across the first-in-human phase 1 program
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.
